Letrozole Tablets, USP is an aromatase inhibitor indicated as an adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Letrozole Tablets, which are therapeutically equivalent to the Novartis Pharmaceuticals’ Femara, will be marketed in 2.5g strength.
APP Pharma president and CEO John Ducker said the approval of Letrozole further expands the company’s oncology product portfolio in this strategically prominent market segment.